Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions. (PubMed, Immunotherapy) - Jul 19, 2026 - "Key findings include: Biological agents, particularly Belimumab and Obinutuzumab, significantly improve complete renal remission (CR) and reduce the risk of end-stage renal disease, breaking through traditional therapeutic bottlenecks. However, rituximab, while effective, carries a higher infection risk (SUCRA = 74.98%). The combination of tacrolimus and mycophenolate mofetil doubled the CR rate compared to monotherapy (OR = 2.85), but requires monitoring for creatinine elevation. Voclosporin use is limited by a high infection risk...Mesenchymal stem cell therapy achieved a 33.7% remission rate. In conclusion, this review provides a comprehensive overview of recent research on LN treatment, offering evidence-based support for clinical decision-making and points out directions for future research."
Journal • Review • Chronic Kidney Disease • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Ophthalmology • Renal Disease • TNFSF12
|
|
Bokun Chen; Feigao Li; Menghao Li; Xiuju Liu; Xizhe Liu
|